Slide 1: Stock exchange cover letter: Investor Presentation
13th May, 2026 (1) BSE Ltd (2) National Stock Exchange of India Ltd Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Scrip Code: 500087 Bandra (East), Mumbai - 400 051 Scrip Symbol: C
Slide 2: Investor Presentation Q4FY26
Investor Presentation Q4FY26 13-05-2026 1
Slide 3: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, pandemic and other factors that could cause actual
Slide 4: Highest-ever Yearly Revenue; Despite Multiple Headwinds
Highest-ever Yearly Revenue; Despite Multiple Headwinds Revenue EBITDA PAT Q4FY26 INR 6,541 Cr INR 997 Cr 15.2% INR 555 Cr 8.5% Margin Margin FY26 INR 28,163 Cr INR 5,925 Cr 21.0% INR 3,879 Cr 13.8% Margin Margin Business Performance Snapshot Emerging Markets & One India North America One Africa Eur
Slide 5: Financial Performance: Q4FY26
Financial Performance : Q4FY26 Revenues INR 6,541 Cr EBITDA INR 997 Cr Revenue1 Break-up Q4FY26 (Consolidated) API and Q4FY26 Q4FY25 Others, 1% (INR Cr) (INR Cr) Emerging markets and Total Revenue from 6,541 6,730 Europe, 12% Operations EBITDA 997 1,538 One Africa, One India, EBITDA % 15.2% 22.8% 19
Slide 6: Financial Performance: FY26
Financial Performance : FY26 Revenues INR 28,163 Cr EBITDA INR 5,925 Cr Revenue1 Break-up FY26 (Consolidated) API, 2% Others, 1% FY 26 FY25 (INR Cr) (INR Cr) Emerging Markets and Europe, 13% Total Revenue from 28,163 27,548 Operations EBITDA 5,925 7,128 One Africa, One India, EBITDA % 21.0% 25.9% 15
Slide 7: Strategic Focus Across Key Financial Metrics
Strategic Focus Across Key Financial Metrics1 INR Cr Revenue EBITDA 27,548 28,163 25.9% 30. 0% 25,455 24.5% 21.0% 22.2% 21,763 22,334 21.0% 25. 0% 20. 0% 15. 0% 10. 0% 4,578 4,952 6,233 7,128 5,925 5.0 % 0.0 % FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 PAT ROIC 33.1% 31.0% 19.1% 23.8% 16.1% 1
Slide 8: Strong Net-Cash: Assembling Resources to Fuel Growth Investments
Strong Net-Cash : Assembling Resources to Fuel Growth Investments; $ 1 Bn+ Net Cash Position in our Balance Sheet INR Cr Total Debt Total Cash1 11,140 10,807 1,056 8,267 803 614 6,273 824 559 520 4,965 438 258 247 92 312 346 356 232 283 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Lease Liabilt
Slide 9: One India: Building a Sustainable Legacy for Enduring Growth
One India1 : Building a Sustainable Legacy for Enduring Growth One India Business Q4FY26 Revenue INR 3,007 Cr FY26 Revenue INR 12,680 Cr Achieved robust double-digit growth across three segments Branded Prescription Trade Generics Consumer Health ❖ Cipla maintained #2 rank in overall ❖ Posted strong
Slide 10: India Branded Prescription: Advancing with Strategic Precision
India Branded Prescription1 : Advancing with Strategic Precision Double-Digit Growth in Key Therapies (%) Rank Our in-house brand franchise, Dytor, has scaled to over Respiratory 11% 1st INR 650 Cr Urology 11% 2nd Anti-diabetes 17% 11th Foracort surpassed the INR 1,000 Cr milestone in IPM Cardiac 12
Slide 11: Portfolio-Enhancing Introductions: Powering a Year of New Launches
Portfolio-Enhancing Introductions : Powering a Year of New Launches Respiratory AMR Urology Anti-diabetes Foracort G Synchrobreathe and Ciphaler Enhancing adherence with A breakthrough for cUTI - Comprehensive SGLT2-led AMR in UTI - Non antibiotic intuitive device-led therapy effective beyond conven
Slide 12: Cipla's Strategic Alliances: Partnerships & Acquisitions
Cipla’s Strategic Alliances : Unlocking Value Through Partnerships & Acquisitions Key Strategic Transactions during the Year Secured rights from Eli Lilly to distribute Partnered with MannKind to launch and promote Yurpeak® in India India’s only rapid acting inhaled insulin Exclusive marketing and d
Slide 13: India Trade Generics: Establishing Deeper Connect with Strong Growth Levers
India Trade Generics : Establishing Deeper Connect with Strong Growth Levers 5,500+ 15,000+ #1 Stockiest Network Pin codes serviced India’s Largest Trade 400+ 150,000+ Generic Business Chemist coverage Retail field team (RTF) Big Brands Bigger 3 Brands with Revenue 4 Brands with Revenue Key New Laun
Slide 14: FY26: Global Consumer Wellness Franchise
FY26 : Global Consumer Wellness Franchise One India One Africa Consumer Brands in One India FY26 Revenue : INR 1,690 Cr Smoking Cold and Pain Relief Respi OTC Cessation Cough Consumer Brands in Hydration Cold & Cough South Africa Pain Respi OTC Management FY26 Revenue : ZAR 1,590 Mn Cold and Skin In
Slide 15: North America: Maintaining Strategic Focus Amid Near-Term Challenges
North America : Maintaining Strategic Focus Amid Near- Term Challenges Key Generic Drug Approvals Liraglutide gVentolin (gSaxenda & gVictoza) Nintedanib Dapagliflozin Key Business Highlights • Albuterol ranked No. 1 with total market1 share at 19.6% (50 million+ inhaler units supplied to the U.S. ma
Slide 16: North America: Advancing Growth through a Strategic Asset Pipeline
North America : Advancing Growth through a Strategic Asset Pipeline Pipeline Progress • 5 assets filed (4 assets expected commercialization in FY 27) Respiratory • 4 assets to be filed in next 24 months Pipeline • 2 assets to be filed with green propellant in next 24 months Peptides & • 8 assets fil
Slide 17: ANDA & NDA Portfolio & Pipeline (As on 31st March 2026)
ANDA & NDA Portfolio & Pipeline (As on 31st March 2026) 200 180 7 160 140 67 120 100 9 80 60 2 2 9 98 0 40 23 3 20 41 24 0 Approved Tentatively Under Approval ANDAs & NDAs Approved ANDAs & NDAs ANDAs & NDAs 1 Cipla Ltd PEPFAR Invagen Partnered ANDAs/NDAs 181 49 55 285 Approved Tentatively Under Appr
Slide 18: One Africa: Continued Progress on Scaling-up Journey
One Africa1 : Continued Progress on Scaling-up Journey $ Mn Q4FY26 $ Mn FY26 15 18 12 14 26 63 63 42 41 17 92 81 68 81 266 287 Q4FY25 Q4FY26 FY25 FY26 SA Private SA Tender North Africa Others (SSA & CGA) SA Private SA Tender North Africa Others (SSA & CGA) Market Segment2 Rank Share Cipla Growth Mar
Slide 19: Progress on ESG goals (India Manufacturing Operations): FY26
Progress on ESG goals (India Manufacturing Operations) : FY26 Goals (India Manufacturing Operations by 2025) Progress : FY 2026 80% reduction in absolute Scope 1 (energy based) and Scope 2 Achieved 83%* reduction from the baseline year, as on CY Dec 2025 emissions from baseline year of FY 2019-20 Wa
Slide 20: Consolidated Profit and Loss Statement Summary (Reported)
Consolidated Profit and Loss Statement Summary (Reported) INR Cr Particulars Q4 FY26 FY26 Revenue from sale of products 6,464 27,712 Other operating income 77 451 Income from operations 6,541 28,163 Material cost 2,249 9,549 Employee benefits expense 1,414 5,366 Other expenses 1,881 7,322 Total expe
Slide 21: Consolidated Balance Sheet Summary (Reported)
Consolidated Balance Sheet Summary (Reported) INR Cr Particulars Mar-26 Mar-25 Net Tangible Assets 7,626 6,586 Goodwill & Intangibles 6,850 4,986 Investments 544 640 Other non-current assets 770 576 Advance tax assets (net) 568 411 Deferred tax assets (net) 748 591 Inventories 6,597 5,642 Cash and C
Slide 22: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 Diksha Maheshwari Investor.Relations@cipla.com For more information, please visit www.cipla.com 21